Quick Answer
CITIUS ONCOLOGY, INC. reported Net Income of -$24.76 million for fiscal year 2025.
CITIUS ONCOLOGY, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$24.76M -17.1% |
-$21.15M -66.6% |
-$12.70M -3434.3% |
$380.8K | — |
| Diluted EPS | -$0.34 -9.7% |
-$0.31 -63.2% |
-$0.19 -258.3% |
$0.12 | — |
| Total Assets | $100.94M +19.6% |
$84.37M +76.7% |
$47.73M -30.0% |
$68.19M +53838.7% |
$126.4K |
| Stockholders Equity | $44.87M -2.8% |
$46.14M +80.7% |
$25.54M -29.6% |
$36.27M +358721.6% |
-$10.1K |
| R&D Expense | $6.42M +30.3% |
$4.93M +16.1% |
$4.24M | — | — |
| Operating Income | -$23.52M -14.3% |
-$20.57M -1930.7% |
-$1.01M -633.5% |
-$138.1K | — |
| Shares Outstanding | 83.51M +16.7% |
71.55M +6.0% |
67.50M +2693.9% |
2.42M +0.0% |
2.42M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $3.94M | — | — |
| Net Income | December 31, 2025 | -$5.53M | +16.9% | -3.1% |
| Diluted EPS | December 31, 2025 | -$0.06 | +33.3% | +25.0% |
| Total Assets | December 31, 2025 | $109.97M | +21.5% | +8.9% |
| Cash and Equivalents | December 31, 2025 | $7.30M | — | +85.9% |
| Stockholders Equity | December 31, 2025 | $58.41M | +41.5% | +30.2% |
| R&D Expense | December 31, 2025 | $1.02M | -19.5% | +8.5% |
| Operating Income | December 31, 2025 | -$5.25M | +17.9% | -6.2% |
| Gross Profit | December 31, 2025 | $3.15M | — | — |
| Shares Outstanding | December 31, 2025 | 84.80M | +18.5% | +1.5% |
- CITIUS ONCOLOGY, INC. reported Net Income of -$24.76 million for fiscal year 2025.
- CITIUS ONCOLOGY, INC. showed a decrease of -17.1% in Net Income compared to the prior fiscal year.
- CITIUS ONCOLOGY, INC. reported Diluted EPS of $0.34 per share (loss) for fiscal year 2025.
- CITIUS ONCOLOGY, INC. showed a decrease of -9.7% in Diluted EPS compared to the prior fiscal year.
- CITIUS ONCOLOGY, INC. reported Total Assets of $100.94 million for fiscal year 2025.
- CITIUS ONCOLOGY, INC. showed an increase of +19.6% in Total Assets compared to the prior fiscal year.
- CITIUS ONCOLOGY, INC. reported Stockholders Equity of $44.87 million for fiscal year 2025.
- CITIUS ONCOLOGY, INC. showed a decrease of -2.8% in Stockholders Equity compared to the prior fiscal year.
- CITIUS ONCOLOGY, INC. reported R&D Expense of $6.42 million for fiscal year 2025.
- CITIUS ONCOLOGY, INC. showed an increase of +30.3% in R&D Expense compared to the prior fiscal year.
- CITIUS ONCOLOGY, INC. reported Operating Income of -$23.52 million for fiscal year 2025.
- CITIUS ONCOLOGY, INC. showed a decrease of -14.3% in Operating Income compared to the prior fiscal year.
- CITIUS ONCOLOGY, INC. reported Shares Outstanding of 83.51 million shares for fiscal year 2025.
- CITIUS ONCOLOGY, INC. showed an increase of +16.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: